GEMP - Gemphire Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.0579
-0.0621 (-5.54%)
As of 12:07PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.1200
Open1.1100
Bid1.040 x 1000
Ask1.080 x 800
Day's Range1.0200 - 1.1212
52 Week Range0.8320 - 11.4300
Volume61,928
Avg. Volume322,038
Market Cap15.091M
Beta (3Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)-2.072
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update

    Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that its Board of Directors is conducting a review of a range of strategic alternatives focused on maximizing stockholder value.  The Company has engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for this process. The Board of Directors has established a committee to oversee this review. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, in-licensing, or other strategic transaction involving the Company.  There can be no assurance that this process will result in Gemphire pursuing any transaction or that any transaction, if pursued, will be completed.

  • GlobeNewswire21 days ago

    Detailed Research: Economic Perspectives on Cocrystal Pharma, Genius Brands International, Gemphire Therapeutics, Global Water Resources, Infrastructure and Energy Alternatives, and Condor Hospitality Trust — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    LIVONIA, Mich., Nov. 08, 2018 -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Aldeyra Therapeutics ...

  • GlobeNewswire3 months ago

    Gemphire Therapeutics Announces Workforce Reduction

    Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), announces today that its Board of Directors has approved a workforce reduction in order to reduce costs and conserve cash resources. This decision was made in light of the previously announced request by the Food and Drug Administration (FDA) for additional pre-clinical data required in order to schedule an End of Phase 2 meeting for gemcabene in the Company’s target dyslipidemia indications. The workforce reduction includes five employees, which represent approximately 33% of the Company’s workforce, as of September 18, 2018.  Two of the five employees include Jeffrey S. Mathiesen, the Company’s Chief Financial Officer, and Lee Golden, the Company’s Chief Medical Officer.  Mr. Mathiesen and Dr. Golden each depart in good standing with the Company.  Mr. Mathiesen has agreed to act as a consultant to Gemphire for a period of eight months, to provide advice on certain financial and accounting matters.

  • Benzinga4 months ago

    The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 6) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: ...

  • What’s behind Gemphire Therapeutics’ Stock Price Rise
    Market Realist5 months ago

    What’s behind Gemphire Therapeutics’ Stock Price Rise

    On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7. After Gemphire announced positive clinical trial results on June 28, its stock price started to rise and closed at $5.24, and on June 29, it rose ~94.47% to $10.19.

  • Why Gemphire Therapeutics Stock Is Rising Today
    Market Realist5 months ago

    Why Gemphire Therapeutics Stock Is Rising Today

    Yesterday, Gemphire Therapeutics (GEMP) announced that its Phase 2b INDIGO-1 trial evaluating investigational first-in-class oral therapy, gemcabene, achieved its primary endpoint of significantly reducing triglyceride levels in Severe Hypertriglyceridemia (or SHTG) patients with baseline serum triglyceride levels greater than 500 mg/dl. The drug also demonstrated a solid safety and tolerability profile and could be safely combined with other drugs. Gemcabene currently holds a method patent in SHTG indication valid until 2032. ...

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Foot Locker, Inc. (NYSE: FL ) stock was trading higher ...

  • Benzinga5 months ago

    Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: Teva Pharmaceuticals and Gemphire Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs 500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco. Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded.

  • Why Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Ownership Structure Is Important
    Simply Wall St.7 months ago

    Why Gemphire Therapeutics Inc’s (NASDAQ:GEMP) Ownership Structure Is Important

    I am going to take a deep dive into Gemphire Therapeutics Inc’s (NASDAQ:GEMP) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of aRead More...

  • Thomson Reuters StreetEvents9 months ago

    Edited Transcript of GEMP earnings conference call or presentation 15-Mar-18 8:30pm GMT

    Q4 2017 Gemphire Therapeutics Inc Earnings Call